



Carmignac Portfolio Grandchildren: Letter from the Fund Manager

Author(s)
Mark Denham, Obe Ejikeme

Published
October 24, 2022 

-3.5%

Carmignac Portfolio Grandchildren's performance in the 3rd quarter of 2022 for the A EUR Acc Share class

+0.1%

Reference indicator's performance in the 3rd quarter of 2022

+6.8%

Annualised performance of the Fund over 3 years versus +8.3% for the reference indicator

During the third quarter of 2022, the total return of Carmignac Portfolio Grandchildren A EUR Acc was -3.5%. This compares to a return on the funds reference indicator of +0.1% over the same period.

Market Environment

In the third quarter, global markets continued to reflect the themes that have driven returns in the first half, in that concern over rising interest rates led to persistent downward pressure on the valuations of relatively highly rated stocks, despite the underlying quality of the companies. This has been exacerbated, all year, by growing concerns over the impact of rising interest rates and the energy crisis on future economic growth and corporate profit growth. **In July equity markets rose on hopes of fast declines in inflation in the US, but these hopes and the July rally came to nought as we have seen a succession of stronger than expected employment and inflation reports**, as well as consistently hawkish commentary from policymakers such as the US Federal Reserve.

Sharp tightening by Central banks and markets' disillusion stirred chaos, with volatile moves across asset classes.The yield on the US 10-year bond first dropped 1 percentage point to 2.5% before rallying to 4% over the period. The MSCI World rallied 20% from its low, then corrected 16% from its August high. Oil prices increased by \$10 before losing \$20 to \$90 a barrel. Finally, the Dollar rallied 9% against a basket of currencies.

Quarterly Performance Review

Our investment approach is to focus on high quality, proven businesses, and these have temporarily been the stocks most adversely affected by rising rates, and so the fund continued to perform worse than the reference indicator last quarter. **Another detractor to our performance was the lack of oil and gas companies**, which do not meet our strong financial or sustainability criteria, but which were among the stronger sectors last quarter, rising 5%, adding to their strong relative returns for the year. **These trends were by far the dominant impacts on our fund**. Bottom-up results for most of our names and indeed across the market were more or less as expected but were seen as backward looking.

In more details, technology stocks were an area of weakness for the fund, led by Nvidia. The stock fell -14% in the quarter for two main reasons. First Q2 numbers confirmed that their Gaming chip activity is in decline with sales falling -33% due to falling end demand and winding down of inventory of old models ahead of new launches in the coming months. Encouragingly the larger datacentre chip division saw continued strong demand, with sales +61%, as cloud computing growth remains high. In addition, though, the US government restricted the sale of leading-edge artificial intelligence application chips to China in September, where Nvidia has exposure to the tune of about 7% of sales. **We maintain our exposure to this name which is at the forefront of chip development** and where notwithstanding these temporary setbacks future growth should be underpinned by growth in virtual reality applications, artificial intelligence, data centre architecture developments and more advanced gaming solutions.

Other technology names also underperformed on interest rate led valuation pressure and some slight economic impact on growth rates on reported numbers. However, the impacted names such as Microsoft, Adobe and ServiceNow still delivered between mid-teen to low 20's percentage growth, which is far above market averages, and **their respective investment theses over the midterm are unchanged. We have added to several of our names in the sector on weakness.**

On a brighter side, several of our names have been able to offset the top-down interest rate led weakness in growth stocks through relentless delivery of good sales and profits growth. LVMH the luxury goods company saw its shares rise 5% as demand for its fashion and leather brands such as Louis Vuitton and Christian Dior continue to grow in United States and in Europe reflecting underlying volume demand and pricing power. While technology companies exposed to multinational spending have seen some slowing in demand, Intuit, the small business accounting software maker, is seeing no slowing in demand from Main Street. Intuit stock rose 7% in the quarter as Q2 results underlined their dominant position, growing more than 20% annually and guiding for group revenues to grow mid-teens.

We also enjoyed a rebound from oversold levels in two of our largest medical technology names in Resmed the leading manufacturer of breathing equipment to treat sleep apnoea rising +11%, and Masimo the leader in equipment to monitor oxygen levels in hospital patients blood rising 15%. Both companies had seen global supply chain disruption caused by covid in Q1 but reported noticeable improvements in Q2, reassuring the market.



Portfolio Changes & Outlook

You will recall that in 2020 we reinforced names in the fund that had been oversold due to businesses being hugely negatively hit by the covid crisis and lockdowns. The leading holding, where we added, was UK listed contract caterer **Compass Group**. Since hugely increasing exposure to the name in March 2020, when its end markets had collapsed and they raised capital to protect their balance sheet, the company has seen revenues consistently improve quarter by quarter to a level now which is above where they entered the covid crisis. **As this stock has recovered nicely, including a 6% increase last quarter, and reached our share price target, we have sold out of most of our exposure.**

The other main change to the structure of the fund last quarter was in the healthcare sector **We added pharmaceutical giant Eli Lilly**, where we believe market expectations for their recently approved weight loss product Mounjaro are still too low despite a very fast sales ramp post launch in the summer. **Increasingly obesity is being recognised as a genuine illness and we are fully exposed to the two main players in this nascent and vast market: Novo Nordisk and now Eli Lilly.**

Central bank hawkishness since the beginning of the year has led to a contraction of market multiples As of the end of 3Q, the MSCI World was trading at 14x forward earnings, down from 20x at the beginning of the year, one of the steepest contractions on record. As we expect rates to plateau somewhat from here, we see the risk of further sharp multiple compression to be limited. **Consequently, we still expect the dominant headwind to change from valuation multiple compression due to rising rates, to growing fear over the impact of rising costs on economies and company profits.** This transition should work in favour of our stocks which have higher visibility and sustainability of profits than the average company and certainly compared with more economically sensitive sectors. So, despite the fund lagging the reference indicator so far this year we are optimistic that this is a great time to be reinforcing positions where we have conviction, as we have done.

Reference indicator: MSCI AC WORLD (USD, Reinvested net dividends) Source: Company website, Bloomberg, Carmignac, 30 September 2022

Carmignac Portfolio Grandchildren

A global, high-conviction equity fund for long-term investors

[Discover the fund page](#)



Carmignac Portfolio Grandchildren A EUR Acc

ISIN: LU1966631001

Recommended
minimum
investment horizon



Main risk of the Fund

EQUITY: The Fund may be affected by stock price variations, the scale of which is dependent on external factors, stock trading volumes or market capitalization.

CURRENCY: Currency risk is linked to exposure to a currency other than the Fund's valuation currency, either through direct investment or the use of forward financial instruments.

DISCRETIONARY MANAGEMENT: Anticipations of financial market changes made by the Management Company have a direct effect on the Fund's performance, which depends on the stocks selected.

The Fund presents a risk of loss of capital.

Marketing communication. Please refer to the KID/KIID, prospectus of the fund before making any final investment decisions. This document is intended for professional clients.

This material may not be reproduced, in whole or in part, without prior authorisation from the Management Company. This material does not constitute a subscription offer, nor does it constitute investment advice. This material is not intended to provide, and should not be relied on for, accounting, legal or tax advice. This material has been provided to you for informational purposes only and may not be relied upon by you in evaluating the merits of investing in any securities or interests referred to herein or for any other purposes. The information contained in this material may be partial information and may be modified without prior notice. They are expressed as of the date of writing and are derived from proprietary and non-proprietary sources deemed by Carmignac to be reliable, are not necessarily all-inclusive and are not guaranteed as to accuracy. As such, no warranty of accuracy or reliability is given and no responsibility arising in any other way for errors and omissions (including responsibility to any person by reason of negligence) is accepted by Carmignac, its officers, employees or agents.

Past performance is not necessarily indicative of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor). The return may increase or decrease as a result of currency fluctuations, for the shares which are not currency-hedged.

Reference to certain securities and financial instruments is for illustrative purposes to highlight stocks that are or have been included in the portfolios of funds in the Carmignac range. This is not intended to promote direct investment in those instruments, nor does it constitute investment advice. The Management Company is not subject to prohibition on trading in these instruments prior to issuing any communication. The portfolios of Carmignac funds may change without previous notice. The reference to a ranking or prize, is no guarantee of the future results of the UCIS or the manager.

Morningstar Rating™ : © Morningstar, Inc. All Rights Reserved. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

Access to the Funds may be subject to restrictions regarding certain persons or countries. This material is not directed to any person in any jurisdiction where (by reason of that person's nationality, residence or otherwise) the material or availability of this material is prohibited. Persons in respect of whom such prohibitions apply must not access this material. Taxation depends on the situation of the individual. The Funds are not registered for retail distribution in Asia, in Japan, in North America, nor are they registered in South America. Carmignac Funds are registered in Singapore as restricted foreign scheme (for professional clients only). The Funds have not been registered under the US Securities Act of 1933. The Funds may not be offered or sold, directly or indirectly, for the benefit or on behalf of a «U.S. person», according to the definition of the US Regulation S and FATCA. The risks, fees and ongoing charges are described in the KID (Key Information Document). The KID must be made available to the subscriber prior to subscription. The subscriber must read the KID. Investors may lose some or all their capital, as the capital in the funds are not guaranteed. The Funds present a risk of loss of capital.

The Funds' prospectus, KIDs, NAVs and annual reports are available at www.carmignac.com, or upon request to the Management Company. Carmignac Portfolio refers to the sub-funds of Carmignac Portfolio SICAV, an investment company under Luxembourg law, conforming to the UCITS Directive. The French investment funds (fonds communs de placement or FCP) are common funds in contractual form conforming to the UCITS or AIFM Directive under French law.

In France, Luxembourg, Sweden: The risks, fees and ongoing charges are described in the KID (Key Information Document). The KID must be made available to the subscriber prior to subscription. The subscriber must read the KID. Investors may lose some or all their capital, as the capital in the funds are not guaranteed. The Funds present a risk of loss of capital. The Funds' prospectus, KIDs, NAV and annual reports are available at www.carmignac.com, or upon request to the Management Company.

In the United Kingdom: the Funds' respective prospectuses, KIIDs and annual reports are available at www.carmignac.co.uk, or upon request to the Management Company, or for the French Funds, at the offices of the Facilities Agent at BNP PARIBAS SECURITIES SERVICES, operating through its branch in London: 55 Moorgate, London EC2R. This document was prepared by Carmignac Gestion, Carmignac Gestion Luxembourg or Carmignac UK Ltd. FP Carmignac ICVC (the "Company") is an Investment Company with variable capital incorporated in England and Wales under registered number 839620 and is authorised by the FCA with effect from 4 April 2019 and launched on 15 May 2019. FundRock Partners Limited is the Authorised Corporate Director (the "ACD") of the Company and is authorised and regulated by the FCA. Registered Office: Hamilton Centre, Rodney Way, Chelmsford, Essex, CM1 3BY, UK; Registered in England and Wales with number 4162989. Carmignac Gestion Luxembourg SA has been appointed as the Investment Manager and distributor in respect of the Company. Carmignac UK Ltd (Registered in England and Wales with number 14162894) has been appointed as a sub-Investment Manager of the Company and is authorised and regulated by the Financial Conduct Authority with FRN:984288.

In Switzerland: the prospectus, KIDs and annual report are available at www.carmignac.ch, or through our representative in Switzerland, CACEIS (Switzerland), S.A., Route de Signy 35, CH-1260 Nyon. The paying agent is CACEIS Bank, Montrouge, Nyon Branch / Switzerland, Route de Signy 35, 1260 Nyon.

The Management Company can cease promotion in your country anytime. Investors have access to a summary of their rights in English on the following links: [UK](#) ; [Switzerland](#) ; [France](#) ; [Luxembourg](#) ; [Sweden](#).